Thu Sep 19 07:22:13 UTC 2024: ## JPMorgan Downgrades Halozyme to Neutral, Despite Increased Price Target

**New York, NY** – JPMorgan Chase has downgraded Halozyme Therapeutics (NASDAQ: HALO) from Overweight to Neutral, despite raising its price target from $52.00 to $57.00. The move follows a significant year-to-date surge in Halozyme’s share price, which has climbed by 69%, outpacing the broader biotech sector.

JPMorgan’s revised stance reflects a reassessment of the stock’s potential for further appreciation. While acknowledging Halozyme’s strong performance, the bank believes the stock, currently trading at $62, is now fully valued. The new price target acknowledges potential value from future product royalties, but the bank feels the current price already captures these expectations.

Despite a bumpy start to the year, Halozyme has demonstrated strong performance with its ENHANZE drug delivery technology. The company reported robust Q2 2024 earnings, driven by a 12% increase in royalty revenue from key products. Partnerships with Roche have led to the US approval of two new treatments, Ocrevus Zunovo and Tecentriq Hybreza, both offering reduced administration times while maintaining safety and efficacy.

Analysts remain optimistic about Halozyme’s future, with H.C. Wainwright maintaining a Buy rating and a $65.00 price target, while TD Cowen upgraded its target to $65.00. Additionally, Halozyme’s patent coverage for ENHANZE in Europe has been extended until March 2029, further solidifying its market position.

Despite this positive outlook, JPMorgan’s downgrade reflects a more conservative view of the stock’s short-term future. Investors seeking further insights into Halozyme’s financials and future prospects can access comprehensive analysis and forecasting on InvestingPro.

Read More